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Oral contraception and eye disease: findings in
two large cohort studies
M P Vessey, P Hannaford, J Mant, R Painter, P Frith, D Chappel
Abstract
Aim—To investigate the relation between
oral contraceptive use and certain eye dis-
eases.
Methods—Abstraction of the relevant data
from the two large British cohort studies
of the eVects of oral contraception, the
Royal College of General Practitioners’
(RCGP) Oral Contraception Study and
the Oxford-Family Planning Association
(Oxford-FPA) Contraceptive Study. Both
cohort studies commenced in 1968 and
were organised on a national basis. Be-
tween them they have accumulated over
850 000 person years of observation in-
volving 63 000 women.
Results—The conditions considered in the
analysis were conjunctivitis, keratitis, iri-
tis, lacrimal disease, strabismus, cataract,
glaucoma, retinal detachment, and retinal
vascular lesions. With the exception of
retinal vascular lesions, there was no con-
sistent evidence of important increases in
risk of eye diseases in users of oral contra-
ception. There was about a twofold in-
crease in the risk of retinal vascular
lesions in recent pill users in both studies
(statistically significant only in the RCGP
study). The increase was not limited to
any specific type of lesion and may well
reflect diagnostic bias.
Conclusion—Oral contraceptive use does
not appear to increase the risk of eye
disease, with the possible exception of
retinal vascular lesions.
(Br J Ophthalmol 1998;82:538–542)
Numerous case reports were published during
the 1960s and 1970s concerning the occur-
rence of a variety of eye disorders in women
using oral contraceptives.1 Epidemiological
studies at that time were few and too small to
provide clear results. More recently, a case-
control study has found no association be-
tween use of oral contraception and early
development of diabetic retinopathy in women
with insulin dependent diabetes.2 The Beaver
Dam survey found that women aged 43–49
who had used oral contraceptives in the past
had a significantly lower prevalence of severe
nuclear sclerosis than women who had never
used oral contraceptives, but there was no sig-
nificant association in older age groups be-
tween past use of oral contraception and
nuclear sclerosis.3 The Blue Mountains Eye
study found no association between prevalence
of cataract and past use of oral contraception in
a population survey of women aged 49 and
over.4 Given the sparsity of the epidemiological
evidence available, we have undertaken an
analysis of the data on eye disease in the two
large British cohort studies of the benefits and
risks of oral contraception—namely, the Royal
College of General Practitioners’ (RCGP) Oral
Contraception Study5 and the Oxford-Family
Planning Association (Oxford-FPA) contra-
ceptive study.6 We summarise our findings
here.
Material and methods
ROYAL COLLEGE OF GENERAL PRACTITIONERS’
ORAL CONTRACEPTION STUDY
During a 14 month period beginning in May
1968, 1400 British general practitioners re-
cruited 23 000 women using oral contracep-
tives and a similar number who had never done
so.5 The two groups were of similar age and all
subjects were married or living as married.
Most (98%) were white. Information collected
at recruitment included smoking habits, parity,
social class, and previous medical history. At
regular intervals since recruitment the general
practitioners have supplied for each woman
still under observation details of any hormonal
preparations prescribed, all newly presenting
episodes of illness and surgery, and, when
appropriate, date and cause of death.
During the course of the study, three oral
contraceptive user groups have evolved—
current users, former users, and never users.
For each calendar month in which a woman
uses the pill, one month is added to the period
of exposure of current users. If that woman
stops the pill, her subsequent periods of obser-
vation are included in the former user group
unless she restarts, in which case she again
contributes from the date of change to the cur-
rent user periods of observation. If a woman
who has never used oral contraceptives at
recruitment subsequently starts to use the pill,
her experience thereafter is allocated to the
appropriate user groups. About one quarter of
the original cohort currently remain under
observation, most women being lost because
they moved from the practice area of the
recruiting doctor; all information is used, how-
ever, up to the time of loss.
The results relate to first ever episodes of a
number of eye diseases occurring both in the
community and in hospital, during the study
using data available at November 1996. Cases
diagnosed before recruitment or during preg-
nancy were excluded, together with the associ-
ated periods of observation. The incidence
rates were directly standardised for age at diag-
nosis using the total RCGP study population
for reference purposes (with the exception of
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Table 1 where the combined populations of
both the RCGP and the Oxford-FPA study
were used as the reference standard). 95%
confidence intervals were calculated on the
assumption that the standard deviation of the
log relative risk is equal to the sum of the recip-
rocals of the observed number of cases in the
two groups being compared.
OXFORD-FAMILY PLANNING ASSOCIATION
CONTRACEPTIVE STUDY
Between 1968 and 1974, 17 032 white married
women, aged 25–39, were recruited at 17
family planning clinics in diVerent parts of
England and Scotland.6 At recruitment, 9654
(56%) of women were taking oral contracep-
tives, 4216 (25%) were using a diaphragm, and
3162 (19%) were using an intrauterine device.
The women were followed up at the clinics or
by post, telephone, or home visits. Information
collected from each woman during follow up
included details of any pregnancies and their
outcome, changes in contraceptive practices,
and reasons for referral to hospital either as an
outpatient or an inpatient. Diagnoses on
discharge from hospital were confirmed by
obtaining copies of discharge letters, summa-
ries, and pathology reports.
Of the 17 032 women in the study, 15 292
(90%) remained under observation on reach-
ing the age of 45. At that age, each woman was
allocated to one of three groups: (a) oral
contraceptives never used, (b) oral contracep-
tives used for a total of 8 years or more, and (c)
other durations of oral contraceptive use. Only
the women in the first two groups (total 9401)
were followed up from then on in the detailed
way described above. Accordingly, women in
group (c) have been omitted from the present
analysis from the age of 45 onwards.
The analysis is based on data collected up to
July 1994. Person years of observation were
computed in the various groups of interest with
the calculation of indirectly standardised rates
(considering age at diagnosis) by the method
described by Vessey et al 6 (with the exception
of Table 1 where a direct method was used).
95% confidence intervals around point esti-
mates of relative risk are based on methods
described by Breslow and Day.7 Analyses were
conducted separately for women aged up to 45
and for women aged 45 or more. The results in
the two sets of analyses were similar; accord-
ingly, only the overall figures are given here.
EYE CONDITIONS EXAMINED
The conditions examined were: conjunctivitis
(International Classification of Diseases, 8th
Revision (ICD8), code 360); keratitis (ICD8
code 363); iritis (ICD8 code 364); lacrimal dis-
ease (ICD8 code 368); strabismus (ICD8 code
373); cataract (ICD8 code 374); glaucoma
(ICD8 code 375); retinal detachment (ICD8
code 376); vascular lesions of retina (ICD8 code
377.0), excluding diabetic retinopathy (ICD8
Table 1 Rates of diVerent eye diseases in the RCGP study and the Oxford-FPA study
Condition
RCGP Study
(No of cases)
Oxford-FPA Study
(No of cases)
Rate ratio
RCGP:Oxford-FPA
Conjunctivitis 100.0 (5646) 5.9 (183) 16.9
Keratitis 3.5 (199) 1.7 (54) 2.0
Iritis 3.4 (187) 1.6 (51) 2.1
Lacrimal disease 4.4 (246) 2.0 (63) 2.2
Strabismus 1.0 (59) 1.1 (33) 0.9
Cataract 2.9 (170) 1.8 (48) 1.6
Glaucoma 2.2 (127) 2.1 (58) 1.0
Retinal detachment 0.7 (38) 1.0 (30) 0.7
Retinal vascular lesions 1.2 (71) 0.9 (25) 1.4
Rates are per 10 000 person years of observation and are directly standardised for age (5 year age
groups) using the combined study populations as the reference standard.
Table 2 Relative risks for the various eye conditions in the RCGP study and the Oxford-FPA study according to oral
contraceptive use. Never users of oral contraceptives have been taken as the reference category. Adjusted for age (5 year age
groups)
Oral contraceptives
Condition Study No cases Ever used Recently used Used in past
Conjunctivitis RCGP 5646 1.1 (1.0–1.1)* 1.2 (1.1–1.3)* 1.0 (1.0–1.1)
Ox-FPA 183 1.3 (0.9–1.9) 1.7 (1.3–2.2)* 1.1 (0.7–1.7)
Keratitis RCGP 199 0.8 (0.6–1.1) 0.9 (0.6–1.4) 0.8 (0.6–1.1)
Ox-FPA 54 1.0 (0.5–1.7) 1.4 (0.7–2.6) 0.7 (0.3–1.4)
Iritis RCGP 187 0.8 (0.6–1.0) 0.7 (0.5–1.0)* 0.6 (0.5–0.9)*
Ox-FPA 51 1.1 (0.6–2.0) 1.1 (0.5–2.4) 1.1 (0.6–2.1)
Lacrimal disease RCGP 246 1.2 (1.0–1.6)* 1.4 (1.0–1.9)* 1.0 (0.8–1.4)
Ox-FPA 63 0.8 (0.5–1.4) 0.8 (0.3–1.6) 0.9 (0.5–1.5)
Strabismus RCGP 59 0.9 (0.6–1.6) 0.6 (0.3–1.3) 1.0 (0.6–1.7)
Ox-FPA 33 0.6 (0.3–1.3) 0.7 (0.3–1.7) 0.5 (0.2–1.2)
Cataract RCGP 170 0.8 (0.6–1.0) 0.3 (0.2–0.6)* 0.8 (0.6–1.1)
Ox-FPA 48 1.6 (0.8–2.9) 3.7 (1.6–8.2)* 1.1 (0.6–2.3)
Glaucoma RCGP 127 1.0 (0.7–1.4) 0.8 (0.4–1.9) 1.0 (0.7–1.5)
Ox-FPA 58 1.6 (0.9–2.0) 1.2 (0.3–3.5) 1.7 (1.0–3.0)
Retinal detachment RCGP 38 0.8 (0.4–1.4) 0.6 (0.3–1.4) 0.6 (0.3–1.3)
Ox-FPA 30 2.3 (1.0–5.7)* 2.1 (0.6–7.0) 2.4 (1.0–6.1)
Retinal vascular lesions RCGP 71 1.3 (0.8–2.0) 2.0 (1.0–3.8)* 1.0 (0.6–1.7)
Ox-FPA 25 1.9 (0.8–4.7) 2.4 (0.4–9.2) 1.9 (0.7–4.6)
*p<0.05.
Periods of observation (person years):
RCGP:
Never used 218 974
Ever used 319 652
Recently used 131 090
Used in past 188 562
Oxford-FPA:
Never used 123 082
Ever used 185 927
Recently used 73 713
Used in past 112 214.
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code 250). The analysis was limited to first
episodes of disease newly presenting during
follow up. Some women had more than one
diagnosis, so when all eye conditions were
combined, the total number of events was
smaller than the sum of the events for each
problem examined separately. Each event was
categorised according to the woman’s contra-
ceptive status at the time of the event. In both
studies, events in current users were combined
with those occurring within 12 months of dis-
continuation of oral contraceptives to produce
a “recent users” category. It should be noted
that this is a routine practice in the Oxford-
FPA study; it is implemented to minimise the
distorting eVects which might otherwise occur
if women presenting with disease in general
practice are taken oV the pill some time before
referral to hospital.
Results
Preliminary analyses of the data for the diVer-
ent eye conditions examining the eVects of age,
parity, social class, and smoking habits showed
age to be the only factor which had an impor-
tant and consistent eVect on risk. Accordingly,
the results presented for the oral contraceptive
comparisons are adjusted for the eVects of age
alone.
Table 1 gives the numbers of cases and the
age standardised rates for the diVerent eye
conditions in the two studies. It should be
borne in mind that the RCGP data include
diagnoses managed entirely in primary care as
well as eye problems referred to hospital. The
Oxford-FPA data on the other hand include
only those eye problems that are referred to
hospital. Not surprisingly, conjunctivitis
emerges as a condition which is managed
almost entirely in general practice. For many of
the other diseases, the rates in the RCGP study
are around twice those in the Oxford-FPA
study; presumably this reflects the fact that not
all patients with the eye diseases listed are
referred to hospital. For strabismus, glaucoma,
and retinal detachment, however, there is little
diVerence between the rates in the two studies.
Hospital referral would be expected in the
great majority of patients presenting with these
conditions.
Table 2 presents the findings for the various
conditions in the two studies according to oral
contraceptive use. The data shown are relative
risks with 95% confidence intervals taking
those never using oral contraceptives as the
reference category. The results for conjunctivi-
tis are consistent with a slight increase in risk in
recent users of oral contraceptives, but the
eVect is small. The suggestion of a reduced risk
of iritis in pill users in the RCGP study is not
supported by the findings in the Oxford-FPA
study. Likewise, the slightly increased risk of
lacrimal disease in recent users of oral contra-
ceptives in the RCGP study is balanced by a
slightly reduced risk in the Oxford-FPA study.
The results of the two studies for cataract are,
however, markedly discrepant. Thus the
RCGP study yields a low relative risk of 0.3
(0.2–0.6) for this condition in recent users of
oral contraceptives while the corresponding
relative risk in the Oxford-FPA study is
markedly elevated at 3.7 (1.6–8.2). It should
be noted, however, that this latter figure is
based on 10 exposed cases and that only three
of these cases underwent cataract surgery.
Limiting the analysis to women undergoing
cataract surgery (28 in all) yields a relative risk
of 2.4 (0.4–8.6) for recent users of oral contra-
ceptives in the Oxford-FPA study. Further
examination of the data on cataract in the two
studies did not provide any additional clues as
to the explanation for the diVerence in the
results. Only 68 women in total in the two
studies were reported to have suVered retinal
detachment. The suggestion of an increased
risk of this condition in pill users in the
Oxford-FPA study was not supported by the
findings in the RCGP study.
Retinal vascular lesions were more common
in recent oral contraceptive users than in never
users in the RCGP study, a diVerence which
just reached statistical significance (relative risk
2.0 (1.0–3.8)). There was a similar increase in
risk in the Oxford-FPA study which did not,
however, approach statistical significance (rela-
tive risk 2.4 (0.4–9.2)). None the less, in view of
the extensive evidence that oral contraceptives
are a cause of vascular events elsewhere in the
body,8 these results are of particular interest
and we subjected them to closer analysis.
Firstly, we reviewed the individual study
records for each woman suVering a retinal vas-
cular lesion and arrived at the results given in
Table 3. Given the small numbers of subjects,
the distributions of the diagnoses in the two
studies are closely similar save that there is a
greater proportion of vitreous haemorrhage
diagnosed in the RCGP study. This may reflect
the lower diagnostic precision that would be
expected in eye problems managed entirely in
primary care. Of the 71 women with retinal
vascular disease in the RCGP study, 24 (34%)
had a previous diagnosis of hypertension and
12 (17%) a previous diagnosis of diabetes mel-
litus (three women had both conditions).
These diagnoses were recorded much less
frequently in the Oxford-FPA study; thus only
three women (12%) had a previous diagnosis
of hypertension and one (4%) of diabetes mel-
litus. These diVerences presumably reflect the
fact that the Oxford-FPA study records disease
events only for women referred to hospital.
We examined the association between oral
contraceptive use and the risk of these specific
retinal vascular diagnoses, but found that the
increase observed in Table 2 was not concen-
trated in any one diagnostic group identified in
Table 3. Indeed, for none of the individual
diagnoses was the relative risk associated with
Table 3 Retinal vascular lesions in the RCGP study and the Oxford-FPA study according
to diagnosis. The data are numbers (%) of patients
Diagnosis RCGP Study Oxford-FPA Study
Retinal vascular occlusion (arterial and unspecified) 10 (14.1) 3 (12.0)
Retinal vein thrombosis 17 (24.0) 8 (32.0)
Retinal haemorrhage 16 (22.5) 8 (32.0)
Vitreous haemorrhage 16 (22.5) 3 (12.0)
Central serous chorioretinopathy 4 (5.6) 1 (4.0)
Other and unspecified lesions 8 (11.3) 2 (8.0)
Total 71 (100.0) 25 (100.0)
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oral contraceptive use significantly greater than
one. Of course, numbers of cases in each
category were small, so the confidence inter-
vals were wide.
Discussion
The RCGP and the Oxford-FPA studies have
accumulated over 850 000 person years of
observation in 63 000 women, including
205 000 person years in current/recent users
and 301 000 person years in past users. It is
reassuring that no consistent evidence of any
major eye problems has emerged from examin-
ation of these data sets which puts into context
the earlier case reports which suggested that
there might be links between use of oral
contraception and eye disorders.
COMPARISON OF RESULTS IN THE TWO DATA SETS
The two data sets are by and large consistent
with each other. Both observed a small, but
significant, increase in risk in conjunctivitis in
recent oral contraceptive pill users. It is
possible that this increase in risk is related, at
least in part, to the diYculties which some oral
contraceptive users experience with contact
lenses.9 A significant increase in risk of lacrimal
disease and a significant reduction in risk of
iritis were observed in the RCGP study, but
these eVects were not confirmed in the
Oxford-FPA study. Nevertheless, there is
considerable overlapping of the confidence
intervals for the estimates of relative risk for
these two conditions in the studies, so that
results are in keeping with each other. Simi-
larly, a significant excess of risk of retinal
detachment in ever users of oral contraception
in the Oxford-FPA study was not observed in
the RCGP study, but again, the confidence
intervals overlapped. The area where there was
the most consistent evidence of an excess risk
was retinal vascular disease. Both studies
estimated the relative risk as being two or
above, statistically significant in the RCGP
study, not so in the Oxford-FPA study. Closer
examination of the diagnoses did not, however,
reveal that the excess risk was confined to a
specific diagnosis.
The one diagnosis where there was a signifi-
cant discrepancy was in cataract, where the
RCGP study found a significant reduction in
risk in oral contraceptive users, while the
Oxford-FPA study found the opposite. It is dif-
ficult to explain this discrepancy, but the
reason possibly lies in ascertainment bias
which is considered below.
POSSIBLE BIASES
There are three important biases that need to
be considered in interpreting the results of
these studies: selection bias, ascertainment
bias, and bias arising from diVerential loss to
follow up.
Selection bias is possible since women with
risk factors such as hypertension, diabetes, or
hyperlipidaemia may have been encouraged by
their general practitioners to use alternative
methods of contraception. Therefore, women
who were prescribed oral contraception were
probably at lower risk of retinal vascular lesions
than women who were not. This will have
reduced any apparent risk of retinal vascular
lesions in users of oral contraception. There-
fore, the excess relative risk of these diagnoses
in these data sets are likely to be an underesti-
mate rather than an overestimate.
Ascertainment bias might occur if doctors
had a lower threshold for considering ophthal-
mic diagnoses in women taking oral contracep-
tion. This is possible, since at the time the
cohorts were being recruited, a number of case
reports were being published linking oral con-
traception to various eye diseases. For exam-
ple, in one review of the ophthalmic complica-
tions of oral contraception, the author
emphasised the “necessity of ophthalmologic
examinations during contraceptive regime”.10
Such diagnostic vigilance is likely to have been
greater in family planning clinics than in
general practice, so may explain why the
estimates of relative risk were higher in the
Oxford-FPA study than in the RCGP study for
users of oral contraception for every diagnosis
except lacrimal disease. Such bias may have
contributed to the diVerences that were
observed with regard to risk of cataract in the
two studies. Ascertainment bias will have
resulted in an overestimate of risk of eye
disease in oral contraceptive users, so will have
counterbalanced the eVects of selection bias,
though it is impossible to say which of these
two biases will have had a greater eVect.
Loss to follow up is an unlikely source of
important bias in these studies. Loss to follow
up in the Oxford-FPA study was low. The
RCGP study experienced greater loss to follow
up, mostly because of women leaving the prac-
tice area. However, the characteristics of pill
users lost to follow up are similar to those of
non-users lost to follow up.11 Furthermore, a
recent analysis of mortality data from the
RCGP study failed to reveal any important
bias resulting from the high rate of attrition.12
Conclusion
With the exception of retinal vascular disease,
there is no consistent evidence of important
increases in risk of eye diseases in users of oral
contraception. It has been useful to consider
the results of these two data sets in combina-
tion, since taken on their own, each suggested
links to specific eye diseases which were not
confirmed by the other study.
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